Financial Performance - Q1 2025 - Total revenue decreased to $306.5 million from $350.4 million in Q1 2024 [7] - GAAP net income decreased to $22.5 million from $36.8 million in Q1 2024 [7] - GAAP earnings per share (diluted) decreased to $0.13 from $0.21 in Q1 2024 [7] - Adjusted EBITDA decreased to $45.6 million from $81.8 million in Q1 2024 [10] - The decrease in revenue and profitability reflects the expiration of royalty on U S net sales of INVEGA SUSTENNA® in August 2024 [8, 11] Revenue Breakdown - Q1 2025 - Total proprietary net sales increased to $244.5 million from $233.5 million in Q1 2024 [12] - VIVITROL® net sales were $101.0 million, compared to $97.7 million in Q1 2024 [12] - ARISTADA® net sales were $73.5 million, compared to $78.9 million in Q1 2024 [12] - LYBALVI® net sales were $70.0 million, reflecting a 23% growth compared to $57.0 million in Q1 2024 [12, 21] Financial Expectations - 2025 - Total revenues are expected to range from $1,340 million to $1,430 million [13] - GAAP net income is projected to be between $175 million and $205 million [13] - Adjusted EBITDA is projected to be between $310 million and $340 million [13] - VIVITROL® net sales are expected to range from $440 million to $460 million [17] - ARISTADA® net sales are expected to range from $335 million to $355 million [17] - LYBALVI® net sales are expected to range from $320 million to $340 million [17]
Alkermes(ALKS) - 2025 Q1 - Earnings Call Presentation